Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our
discussion forums.
Hi James Anthony, I'm so sorry you are going through this and so very young. It' s true that some people benefit for years with chemo and targeted therapies. With the...
Hi siigs, I'm sorry you're having health issues. They don't sound like pancoast tumor symptoms. A consult with a pulmonologist can help to understand your chest symptoms and work toward alleviating...
Hi Lonnie,
Yes, the info in last year's OncTalk was up to date at that moment. I think it would be well worth the watch along with videos in our 2025...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.